BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34051683)

  • 41. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
    Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
    Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiparametric functional MRI and
    Martens RM; Koopman T; Lavini C; Ali M; Peeters CFW; Noij DP; Zwezerijnen G; Marcus JT; Vergeer MR; Leemans CR; de Bree R; de Graaf P; Boellaard R; Castelijns JA
    Eur Radiol; 2021 Feb; 31(2):616-628. PubMed ID: 32851444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnetic resonance imaging after external beam radiotherapy and concurrent chemotherapy for locally advanced cervical cancer helps to identify patients at risk of recurrence.
    Angeles MA; Baissas P; Leblanc E; Lusque A; Ferron G; Ducassou A; Martínez-Gómez C; Querleu D; Martinez A
    Int J Gynecol Cancer; 2019 Mar; 29(3):480-486. PubMed ID: 30712019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multi-parametric MRI in cervical cancer: early prediction of response to concurrent chemoradiotherapy in combination with clinical prognostic factors.
    Yang W; Qiang JW; Tian HP; Chen B; Wang AJ; Zhao JG
    Eur Radiol; 2018 Jan; 28(1):437-445. PubMed ID: 28779395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of outcome using pretreatment
    Lucia F; Visvikis D; Desseroit MC; Miranda O; Malhaire JP; Robin P; Pradier O; Hatt M; Schick U
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):768-786. PubMed ID: 29222685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.
    Guo L; Liu X; Wang L; Sun H; Huang K; Li X; Tang F; Li S; Yuan X; Wang C
    Int J Gynecol Cancer; 2015 Jun; 25(5):910-8. PubMed ID: 25867278
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort.
    Endo D; Todo Y; Okamoto K; Minobe S; Kato H; Nishiyama N
    J Gynecol Oncol; 2015 Jan; 26(1):12-8. PubMed ID: 25310853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer.
    Nakamura K; Joja I; Kodama J; Hongo A; Hiramatsu Y
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):283-90. PubMed ID: 22072286
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer.
    Hong JH; Jung US; Min KJ; Lee JK; Kim S; Eo JS
    Nucl Med Commun; 2016 Aug; 37(8):843-8. PubMed ID: 27058362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
    Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D
    Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nomograms Combining Clinical and Imaging Parameters to Predict Recurrence and Disease-free Survival After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
    Zhang Y; Liu L; Zhang K; Su R; Jia H; Qian L; Dong J
    Acad Radiol; 2023 Mar; 30(3):499-508. PubMed ID: 36050264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pretreatment Mean Apparent Diffusion Coefficient Is Significantly Correlated With Event-Free Survival in Patients With International Federation of Gynecology and Obstetrics Stage Ib to IIIb Cervical Cancer.
    Himoto Y; Fujimoto K; Kido A; Baba T; Tanaka S; Morisawa N; Koyasu S; Konishi I; Togashi K
    Int J Gynecol Cancer; 2015 Jul; 25(6):1079-85. PubMed ID: 25853385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer.
    Sala E; Micco M; Burger IA; Yakar D; Kollmeier MA; Goldman DA; Gonen M; Park KJ; Abu-Rustum NR; Hricak H; Vargas HA
    Int J Gynecol Cancer; 2015 Oct; 25(8):1461-7. PubMed ID: 26397068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined dynamic DCE-MRI and diffusion-weighted imaging to evaluate the effect of neoadjuvant chemotherapy in cervical cancer.
    Feng Y; Liu H; Ding Y; Zhang Y; Liao C; Jin Y; Ai C
    Tumori; 2020 Apr; 106(2):155-164. PubMed ID: 31736439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High standardized uptake values of
    Yang Z; Wu JR; Wei LL; Liao GX; Yang CJ; Jin GQ; Xiao GY; Su DK
    Hell J Nucl Med; 2019; 22(2):96-102. PubMed ID: 31273350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses.
    Lund KV; Simonsen TG; Kristensen GB; Rofstad EK
    Radiat Oncol; 2020 Apr; 15(1):79. PubMed ID: 32293487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of out-of-field recurrence after chemoradiotherapy for cervical cancer using a combination model of clinical parameters and magnetic resonance imaging radiomics: a multi-institutional study of the Japanese Radiation Oncology Study Group.
    Ikushima H; Haga A; Ando K; Kato S; Kaneyasu Y; Uno T; Okonogi N; Yoshida K; Ariga T; Isohashi F; Harima Y; Kanemoto A; Ii N; Wakatsuki M; Ohno T
    J Radiat Res; 2022 Jan; 63(1):98-106. PubMed ID: 34865079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent.
    Narayan K; Fisher RJ; Bernshaw D; Shakher R; Hicks RJ
    Int J Gynecol Cancer; 2009 Jul; 19(5):912-8. PubMed ID: 19574784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.